BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36058847)

  • 21. Fibroblast growth factor 23 is independently associated with renal magnesium handling in patients with chronic kidney disease.
    Grigore TV; Zuidscherwoude M; Witasp A; Barany P; Wernerson A; Bruchfeld A; Xu H; Olauson H; Hoenderop J
    Front Endocrinol (Lausanne); 2022; 13():1046392. PubMed ID: 36699036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease.
    Goto S; Nakai K; Kono K; Yonekura Y; Ito J; Fujii H; Nishi S
    Clin Exp Nephrol; 2014 Dec; 18(6):925-31. PubMed ID: 24578219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial.
    Tsai WC; Wu HY; Peng YS; Hsu SP; Chiu YL; Yang JY; Chen HY; Pai MF; Lin WY; Hung KY; Chu FY; Tsai SM; Chien KL
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1475-1483. PubMed ID: 31519550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
    Tomida K; Hamano T; Ichimaru N; Fujii N; Matsui I; Nonomura N; Tsubakihara Y; Rakugi H; Takahara S; Isaka Y
    Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
    Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship Between Dietary Phosphate Intake and Biomarkers of Bone and Mineral Metabolism in Australian Adults With Chronic Kidney Disease.
    Conley M; Campbell KL; Hawley CM; Lioufas NM; Elder GJ; Badve SV; Pedagogos E; Milanzi E; Pascoe EM; Valks A; Toussaint ND
    J Ren Nutr; 2022 Jan; 32(1):58-67. PubMed ID: 34509358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism.
    Sakan H; Nakatani K; Asai O; Imura A; Tanaka T; Yoshimoto S; Iwamoto N; Kurumatani N; Iwano M; Nabeshima Y; Konishi N; Saito Y
    PLoS One; 2014; 9(1):e86301. PubMed ID: 24466013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The regulation of FGF23 under physiological and pathophysiological conditions.
    Rausch S; Föller M
    Pflugers Arch; 2022 Mar; 474(3):281-292. PubMed ID: 35084563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease.
    Sakoh T; Nakayama M; Tsuchihashi T; Yoshitomi R; Tanaka S; Katafuchi E; Fukui A; Shikuwa Y; Anzai N; Kitazono T; Tsuruya K
    Metabolism; 2016 Oct; 65(10):1498-507. PubMed ID: 27621185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
    Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
    Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ironing out the cross talk between FGF23 and inflammation.
    David V; Francis C; Babitt JL
    Am J Physiol Renal Physiol; 2017 Jan; 312(1):F1-F8. PubMed ID: 27582104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Importance of Phosphate Control in Chronic Kidney Disease.
    Tsuchiya K; Akihisa T
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
    Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
    BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibroblast growth factor 23, but not parathyroid hormone, is associated with urinary phosphate regulation in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Hasegawa S; Tanaka S; Eriguchi M; Nakano T; Masutani K; Ooboshi H; Kitazono T
    Ther Apher Dial; 2015 Feb; 19(1):73-80. PubMed ID: 25195562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
    Shalhoub V; Shatzen EM; Ward SC; Davis J; Stevens J; Bi V; Renshaw L; Hawkins N; Wang W; Chen C; Tsai MM; Cattley RC; Wronski TJ; Xia X; Li X; Henley C; Eschenberg M; Richards WG
    J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
    J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
    Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.